Kowa is doing okay. Livalo still will produce revenue and more for this year. Livalo will pay the bills in America. Kowa in Japan at the headquarters they are a smart company and the people running it are smart. They are very wise and conservative on spending even in America. They aren’t paying reps much if any on Livalo this year because of the IC structure, only quarterly payouts, and now the BlinkRx structure you have to hit to even get paid (only a few reps will hit it). Trust me they haven’t pay out much the whole year on Livalo but the reps are still selling Livalo strongly with new all time highs. Stay hopeful out there! And sell Livalo and BLINKRX!
anonymous
Guest
anonymous
Guest
Hi FriendKowa is doing okay. Livalo still will produce revenue and more for this year. Livalo will pay the bills in America. Kowa in Japan at the headquarters they are a smart company and the people running it are smart. They are very wise and conservative on spending even in America. They aren’t paying reps much if any on Livalo this year because of the IC structure, only quarterly payouts, and now the BlinkRx structure you have to hit to even get paid (only a few reps will hit it). Trust me they haven’t pay out much the whole year on Livalo but the reps are still selling Livalo strongly with new all time highs. Stay hopeful out there! And sell Livalo and BLINKRX!
No offense, but you are either new to the industry or new to Kowa. Let's take BEST case scenario.
500 million in sales of Livalo for 2023. (NOT A CHANCE )
They pay 60% rebates on 80% of that that would be 240 million in rebates.
The medi-medi business probably another 5% is a net loss so another 25 million to the various states.
Salaries for all of employees: 25 million?
Sample 15 to 20 million
Marketing and other marketing expenses 5 million?
So a minimum of 300 million dollars on the debit side of the ledger and NO TAXES or IC has been paid and that is with an estimate of the best year ever in an 11 month year!
When Livalo hits generic in November BLINK won't save them. Now you understand the lack of rehiring being done. They can keep the lights on this year but they go NEGATIVE in 2024. Every Seglentis script currently loses money. Do that math.
anonymous
Guest
anonymous
Guest
Hi Friend
No offense, but you are either new to the industry or new to Kowa. Let's take BEST case scenario.
500 million in sales of Livalo for 2023. (NOT A CHANCE )
They pay 60% rebates on 80% of that that would be 240 million in rebates.
The medi-medi business probably another 5% is a net loss so another 25 million to the various states.
Salaries for all of employees: 25 million?
Sample 15 to 20 million
Marketing and other marketing expenses 5 million?
So a minimum of 300 million dollars on the debit side of the ledger and NO TAXES or IC has been paid and that is with an estimate of the best year ever in an 11 month year!
When Livalo hits generic in November BLINK won't save them. Now you understand the lack of rehiring being done. They can keep the lights on this year but they go NEGATIVE in 2024. Every Seglentis script currently loses money. Do that math.
You seem to know more than the average rep/ DM. Tell us please, why are they keeping 240 of us around? I’d love to hear a decent explanation.
anonymous
Guest
anonymous
Guest
Why was the sales force reduced from 311 to 240?
anonymous
Guest
anonymous
Guest
1. At Seglentis launch there were 311. That is 25% decrease.You seem to know more than the average rep/ DM. Tell us please, why are they keeping 240 of us around? I’d love to hear a decent explanation.
2. Kowa has a long term vision for the organization, maybe Ophthalmology in a few years.
3. Japan carried the organization for 5 years losing money. They are a family owned organization not indebted to shareholders. That is why Kowa exists today
4. They may have an obligation to Seglentis?
5. Japan can add. I don't think they will remain an organization as it currently exists. Kowa is not investing in their product Livalo after November. It would be other companies at BEST.
You don't need to be in managed care or a manager to do that math.
Polish that resume
anonymous
Guest
anonymous
Guest
Hi Friend
No offense, but you are either new to the industry or new to Kowa. Let's take BEST case scenario.
500 million in sales of Livalo for 2023. (NOT A CHANCE )
They pay 60% rebates on 80% of that that would be 240 million in rebates.
The medi-medi business probably another 5% is a net loss so another 25 million to the various states.
Salaries for all of employees: 25 million?
Sample 15 to 20 million
Marketing and other marketing expenses 5 million?
So a minimum of 300 million dollars on the debit side of the ledger and NO TAXES or IC has been paid and that is with an estimate of the best year ever in an 11 month year!
When Livalo hits generic in November BLINK won't save them. Now you understand the lack of rehiring being done. They can keep the lights on this year but they go NEGATIVE in 2024. Every Seglentis script currently loses money. Do that math.
You sound unhinged. Kowa pharmaceuticals in America is profitable with Livalo and has been for a while now. So your math is unhinged. Do you even know how profitable the pharmaceutical industry is? Employees are paid accordingly and most companies already know what they will pay out years in advance based on profits. This is at EVERY company. You know Kowa pays the sales employees for the first 3 months and the rest of the year is profit to themselves. For R&D, further investments, etc. Kowa Japan isn’t that dumb and is profiting still on Livalo more than your math is adding up.
anonymous
Guest
anonymous
Guest
Why was the sales force reduced from 311 to 240?
They never downsized. They forced reps out that are lazy and don’t want to sell SEG. SEG is a hard sell and is very different than Livalo. Pharmacy’s don’t help either. Good luck out there.
anonymous
Guest
anonymous
Guest
So 25% of the sales was lazy? Hmm... Kowa is saying it was not a sales force "downsizing" because if they did they would have to pay the Federal government back the millions they took in Covid funds. Stop the BS
anonymous
Guest
anonymous
Guest
So 25% of the sales was lazy? Hmm... Kowa is saying it was not a sales force "downsizing" because if they did they would have to pay the Federal government back the millions they took in Covid funds. Stop the BS
Yes Kowa told reps our jobs were secure during Covid because they were given PPP loans. The forcing out started last year. Remember during Covid Kowa forced reps back out after like 2 months. All other pharmaceutical companies was on lock down for years… my point Kowa has cash and doing okay. Livalo is still making them profits and they aren’t paying reps on it. Unless you meet the high BLINKRX requirements or in the past the IC requirements.
anonymous
Guest
anonymous
Guest
LOLYou sound unhinged. Kowa pharmaceuticals in America is profitable with Livalo and has been for a while now. So your math is unhinged. Do you even know how profitable the pharmaceutical industry is? Employees are paid accordingly and most companies already know what they will pay out years in advance based on profits. This is at EVERY company. You know Kowa pays the sales employees for the first 3 months and the rest of the year is profit to themselves. For R&D, further investments, etc. Kowa Japan isn’t that dumb and is profiting still on Livalo more than your math is adding up.
Whistling past the graveyard.
The pharmaceutical industry is profitable do you know how much of the business disappears on the day after a product goes generic?
The PPP revenue was a blessing and a curse. They had to retain employees, dropped a lot of money to the profit at Kowa and like the vaccine manufacturers have to try and find that Covid revenue somewhere else.
Where is that Montgomery group going to find it with JM at the helm? You know the answer. How long has he been promising a co-promote to you?
The top 1/3 are still making less than "normal" pharma bonuses but 2/3 of you need to be picking up some UBER shifts.
It is hilarious to me that so many people can pretend it's all great. I understand that if you are JM or JF where are they going when this all goes down, but the rest of you?
anonymous
Guest
anonymous
Guest
You sound unhinged. Kowa pharmaceuticals in America is profitable with Livalo and has been for a while now. So your math is unhinged. Do you even know how profitable the pharmaceutical industry is? Employees are paid accordingly and most companies already know what they will pay out years in advance based on profits. This is at EVERY company. You know Kowa pays the sales employees for the first 3 months and the rest of the year is profit to themselves. For R&D, further investments, etc. Kowa Japan isn’t that dumb and is profiting still on Livalo more than your math is adding up.
Are you new here?